J.M. Hum, E.L. Clinkenbeard, C. Ip, T.A. Cass, M.R. Allen, and K.E. White. The metabolic bone disease associated with the Hyp mutation is independent of osteoblastic HIF1α expression. 2017. Bone Reports; 6:38-43. PMID: 28377980; PMCID: PMC5365303.
E.L. Clinkenbeard, K.R. Stayrook, H.N.Appaiah, M.R. Hanudel, E.G. Farrow, T.A. Cass, L.J. Summers, C.S. Ip, J.M. Hum, J.C. Thomas, M. Ivan, B.R. Richine, R.J. Chan, T.L. Clemens, E. Schipani, Y. Sabbagh, L. Xu, E.F. Srour, M.B. Alvarez, M.A. Kacena, I.B. Salusky, T. Ganz, E. Nemeth and K.E. White. Erythropoietin (EPO) Induces Fibroblast growth factor-23 (FGF23), revealing novel roles for bone and bone marrow in renal failure. 2017. Hematologica, In press. PMID: 28818868; DOI: 10.3324/haematol.2017.167882.
J.C. Fleet, R.A. Replogle, P. Reyes-Fernandez, L. Wang, M. Zhang, E.L. Clinkenbeard, and K.E. White. Gene-by-diet interactions affect serum 1,25 dihydroxyvitamin D levels in male BXD recombinant inbred mice. 2016. Endocrinology, 157(2):470-81. PMID: 26587785; PMCID: PMC4733130.
E.L. Clinkenbeard, T.A. Cass, P. Ni, J.M. Hum, T. Bellido, M.R. Allen, and K.E. White. Conditional deletion of murine Fgf23: Interruption of the normal skeletal responses to phosphate challenge and rescue of genetic hypophosphatemia. 2016. J Bone Mineral Rsch, 31(6):1247-57. PMID: 26792657; PMCID: PMC4891276.
J.M. Hum, L.M. O’Bryan, E.L. Clinkenbeard, R.C. Smith, and K.E. White. A soluble form of αKlotho prevents aortic calcification and disease phenotypes during chronic hyperphosphatemia. 2016. JASN; 28(4):1162-1174. PMID: 27837149; PMCID: PMC5373441.